Neutralizing Antibody Formation with OnabotulinumtoxinA (BOTOX®) Treatment from Global Registration Studies across Multiple Indications: A Meta-Analysis
Joseph Jankovic(Baylor College of Medicine), Jie Shen(Xinjiang Medical University), Ritu Singh(Boston Scientific (United States)), Terry Boodhoo(AbbVie (United States)), Jean Carruthers(University of British Columbia), John Soliman(AbbVie (United States)), Patricia Ogilvie, Mitchell F. Brin(AbbVie (United States)), Mayssa Attar(AbbVie (United States)), Irina Yushmanova(AbbVie (United States)), Markus Naumann(University Hospital Augsburg), Swati Gupta(AbbVie (United States))
Cited by 39
Related Papers
The Parkinson Progression Marker Initiative (PPMI)
|Progress in Neurobiology|2011|1.9k
Variable expression of Parkinson's disease
|Neurology|1990|1.3k
The early-onset torsion dystonia gene (DYT1) encodes an ATP-binding protein
|Nature Genetics|1997|1k
Past, present, and future of Parkinson's disease: A special essay on the 200th Anniversary of the Shaking Palsy
|Movement Disorders|2017|846